ABSTRACT
O envelhecimento é um processo acompanhado por uma série de mudanças físicas, fisiológicas e psicológicas, além de ser caracterizado pelo declínio de diferentes funções motoras e cognitivas, que afetam a independência do idoso. Particularmente na mulher, um acompanhante inevitável do envelhecimento é a menopausa. Desse modo, é natural o interesse em medidas terapêuticas que possam ser utilizadas para minimizar os sintomas da menopausa, bem como o prejuízo motor e cognitivo. Assim, o presente estudo teve como objetivo (i) avaliar o efeito da idade nos aspectos comportamentais, neuroquímicos e de ácidos graxos poli-insaturados em ratas jovens (3 meses de idade), de meia-idade (12 meses de idade) e senescentes (18 meses de idade); e, (ii) avaliar os efeitos da administração prolongada (90 dias) de diferentes doses (50, 100 e 200 mg/kg/dia) de isoflavonas (ISOs) no perfil comportamental, na análise bioquímica sérica e de estradiol, na quantificação dos níveis de neurotransmissores encefálicos e achados anatomopatológicos em ratas de meia-idade. Os resultados da primeira etapa mostraram que: ratas com 12 e 18 meses de idade apresentaram: 1) diminuição da frequência de levantar e de grooming no campo aberto; 2) aumento do comportamento tipo-ansioso no labirinto em cruz elevado e na caixa claro-escuro; 3) prejuízo na memória espacial observada no labirinto de Barnes; 4) diminuição, sobretudo, nos níveis de dopamina e de seus metabólitos no córtex pré-frontal (CPF), no hipotálamo, no hipocampo e no estriado; 5) diminuição dos níveis dos hidróxidos 12 e 15/14 do ácido araquidônico (AA) no CPF de ratas com 18 meses de idade. Esses dados em conjunto evidenciam prejuízo motor e cognitivo, aumento do comportamento tipo-ansioso, bem como redução nos níveis de monoaminas e dos hidróxidos do AA com o avanço da idade das ratas. Em relação ao tratamento prolongado com diferentes doses de ISOs em ratas de meia-idade, os resultados mostraram que: 1) não houve alterações motoras e no comportamento tipo-ansioso; 2) evidenciou melhora no desempenho cognitivo espacial; 3) mostrou aumento nos níveis séricos de estradiol e 4) promoveu aumento nos níveis de glutamato e de GABA no CPF e no hipotálamo. Esses achados sugerem que o tratamento prolongado com diferentes doses de ISOs em ratas de meia-idade, foi capaz de melhorar a performance cognitiva espacial e esse efeito pode ser associado ao aumento dos níveis de estrógeno, bem como ao aumento dos níveis de glutamato e de GABA no córtex pré-frontal e no hipotálamo, evidenciando também um possível efeito neuroprotetor das ISOs em ambas regiões.
Aging is a process accompanied by a series of physical, physiological and psychological changes, besides being characterized by the decline of different motor and cognitive functions, which affect the independence of the elderly. Specifically, in women, an inevitable companion of aging is menopause. Therefore, it is of high interest therapeutic procedures that can be used to reduce the symptoms of menopause, as well as motor and cognitive impairment. Thus, the present study aimed to (i) evaluate the effect of age on behavioral, neurochemical and polyunsaturated fatty acids aspects in young (3 months old), middle-aged (12 months old) and senescent (18 months of age) female rats; and (ii) to evaluate the effects of prolonged (90 days) administration of different doses (50, 100 and 200 mg/kg/day) of isoflavones (ISOs) in the behavioral profile, biochemical and estradiol serum analysis, brain neurotransmitters levels and anatomopathological findings in middle-aged rats. Our first results showed that rats at 12 and 18 months of age: 1) presented a decrease in rearing and grooming frequency in the open field; 2) increase of anxiety-like behavior in the elevated plus maze and light-dark box; 3) spatial memory impairment observed in the Barnes maze; 4) a decrease mainly in the levels of dopamine and its metabolites in the prefrontal cortex (PFC), hypothalamus, hippocampus and striatum; 5) decreased levels of 12 and 15/14 arachidonic acid (AA) hydroxides in the PFC in 18-month old rats . These data altogether show motor and cognitive impairment, increase in anxiety-like behavior, as well as reductions in monoamine levels and AA hydroxides as the rat age progresses. Regarding the prolonged treatment with different doses of ISOs in middle-aged rats, the results showed that: 1) there were no motor or anxiety-like behavior alterations; 2) there was an improvement in spatial cognitive performance; 3) increase in serum estradiol levels and 4) increase in glutamate and GABA levels in the PFC and hypothalamus. These findings suggest that prolonged treatment with different doses of ISOs could improve spatial cognitive performance and that this effect may be associated with increased estrogen levels, as well as increased levels of glutamate and GABA in the prefrontal cortex and hypothalamus, evidencing a possible neuroprotective effect of ISOs in both regions.
Subject(s)
Animals , Female , Rats , Behavior , Isoflavones/adverse effects , Aging/metabolism , Isoflavones/administration & dosage , Memory , Menopause/physiology , PhytoestrogensABSTRACT
OBJECTIVE: This study aims to evaluate the effects of soy isoflavones on breast tissue in postmenopausal women. METHODS: In this randomized, double-blind, placebo-controlled study, 80 women (aged ≥ 45 y and with amenorrhea >12 mo) with vasomotor symptoms were randomized to receive either 250 mg of standardized soy extract corresponding to isoflavone 100 mg/day (n = 40) or placebo (n = 40) for 10 months. Breasts were evaluated through mammographic density and breast parenchyma using ultrasound (US) at baseline and 10-month follow-up. Independent t test, analysis of variance, Mann-Whitney U test, and χ2 trend test were used in statistical analysis. RESULTS: Baseline clinical characteristics showed no significant differences between the isoflavone group and the placebo group, with mean (SD) age of 55.1 (6.0) and 56.2 (7.7) years, mean (SD) menopause duration of 6.6 (4.8) and 7.1 (4.2) years, and mean (SD) body mass index of 29.7 (5.0) and 28.5 (4.9) kg/m2, respectively (P > 0.05). The study was completed by 32 women on isoflavone and 34 women on placebo. The groups did not differ in mammographic density or breast parenchyma by US (P > 0.05). Within each group, the baseline and final moments did not differ in mammography or US parameters significantly (P > 0.05). CONCLUSIONS: The use of soy isoflavone extract for 10 months does not affect breast density, as assessed by mammography and US, in postmenopausal women.
Subject(s)
Breast Neoplasms , Breast/drug effects , Glycine max/chemistry , Isoflavones/administration & dosage , Isoflavones/adverse effects , Mammary Glands, Human/abnormalities , Postmenopause , Body Mass Index , Breast Density , Double-Blind Method , Female , Genistein/blood , Humans , Isoflavones/blood , Mammography , Middle Aged , Placebos , Plant Extracts/administration & dosage , Ultrasonography, MammarySubject(s)
Humans , Female , Breast Neoplasms/etiology , Menopause/drug effects , Estrogen Replacement Therapy/adverse effects , Hormone Replacement Therapy/adverse effects , Estrogens/adverse effects , Progestins/adverse effects , Climacteric , Review Literature as Topic , Cimicifuga/adverse effects , Risk Factors , Evidence-Based Medicine , Observational Studies as Topic , Isoflavones/adverse effectsABSTRACT
Dietary soy is thought to be cancer-preventive; however, the beneficial effects of soy on established breast cancer is controversial. We recently demonstrated that dietary daidzein or combined soy isoflavones (genistein, daidzein, and glycitein) increased primary mammary tumor growth and metastasis. Cancer-promoting molecules, including eukaryotic protein synthesis initiation factors (eIF) eIF4G and eIF4E, were up-regulated in mammary tumors from mice that received dietary daidzein. Herein, we show that increased eIF expression in tumor extracts of mice after daidzein diets is associated with protein expression of mRNAs with internal ribosome entry sites (IRES) that are sensitive to eIF4E and eIF4G levels. Results with metastatic cancer cell lines show that some of the effects of daidzein in vivo can be recapitulated by the daidzein metabolite equol. In vitro, equol, but not daidzein, up-regulated eIF4G without affecting eIF4E or its regulator, 4E-binding protein (4E-BP), levels. Equol also increased metastatic cancer cell viability. Equol specifically increased the protein expression of IRES containing cell survival and proliferation-promoting molecules and up-regulated gene and protein expression of the transcription factor c-Myc. Moreover, equol increased the polysomal association of mRNAs for p 120 catenin and eIF4G. The elevated eIF4G in response to equol was not associated with eIF4E or 4E-binding protein in 5' cap co-capture assays or co-immunoprecipitations. In dual luciferase assays, IRES-dependent protein synthesis was increased by equol. Therefore, up-regulation of eIF4G by equol may result in increased translation of pro-cancer mRNAs with IRESs and, thus, promote cancer malignancy.
Subject(s)
Breast Neoplasms/metabolism , Equol/adverse effects , Eukaryotic Initiation Factor-4G/biosynthesis , Gene Expression Regulation, Neoplastic/drug effects , Glycine max/chemistry , Phytoestrogens/adverse effects , Protein Biosynthesis/drug effects , Animals , Breast Neoplasms/genetics , Breast Neoplasms/pathology , Cell Line, Tumor , Dietary Supplements/adverse effects , Equol/chemistry , Equol/pharmacology , Eukaryotic Initiation Factor-4E/biosynthesis , Eukaryotic Initiation Factor-4E/genetics , Eukaryotic Initiation Factor-4G/genetics , Female , Gene Expression Regulation, Neoplastic/genetics , Humans , Isoflavones/adverse effects , Isoflavones/pharmacology , Mice , Mice, Nude , Neoplasm Transplantation , Phytoestrogens/chemistry , Phytoestrogens/pharmacology , Protein Biosynthesis/genetics , Proto-Oncogene Proteins c-myc/biosynthesis , Proto-Oncogene Proteins c-myc/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Neoplasm/genetics , RNA, Neoplasm/metabolism , Transplantation, Heterologous , Up-Regulation/drug effects , Up-Regulation/geneticsABSTRACT
Calophyllum species are sources of calanolides, which inhibit human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT). The hexane extract of the leaves from C. brasiliense collected in Soconusco, State of Chiapas, Mexico, analyzed by HPLC showed to contain apetalic acid, calanolides B, and C. It showed potent anti-HIV-1 RT inhibition (IC(50)=20.2 µg/ml), but was not toxic in mice (LD(50)=1.99 g/kg). The histological study of the mice treated at the highest dose revealed no alteration on hepatocytes, and an increase in the number of spleen megakaryocytes. These results suggest this extract is suitable to continue studies for developing a phytodrug against HIV-1.
Subject(s)
Calophyllum/chemistry , HIV Reverse Transcriptase/antagonists & inhibitors , Isoflavones/pharmacology , Phytotherapy , Plant Extracts/pharmacology , Pyranocoumarins/pharmacology , Reverse Transcriptase Inhibitors/pharmacology , Animals , Calophyllum/adverse effects , HIV Infections/drug therapy , HIV Infections/virology , HIV-1/enzymology , Hepatocytes/drug effects , Humans , Isoflavones/adverse effects , Isoflavones/analysis , Male , Megakaryocytes/drug effects , Mexico , Mice , Plant Extracts/adverse effects , Plant Extracts/chemistry , Plant Leaves , Pyranocoumarins/adverse effects , Pyranocoumarins/analysis , Reverse Transcriptase Inhibitors/adverse effects , Reverse Transcriptase Inhibitors/analysis , Spleen/drug effectsABSTRACT
OBJECTIVE: To evaluate the effects of treatment with Trifolium pratense on climacteric symptoms and sexual satisfaction in postmenopausal women. METHODS: This is a prospective, randomized, double-blind, placebo-controlled study. Initially, 120 women aged 45-65 years with menopausal symptoms, more than 12-month amenorrhea and no treatment in the past six months were selected. The participants were then divided into two groups: TG receiving 40 mg Trifolium pratense, 1 capsule/day; PG receiving placebo capsules containing lactose (control), 1 capsule/day. The duration of treatment was 12 months. The patients underwent clinical and laboratory evaluation before treatment and at four, eight and 12 months of treatment. The Kupperman Menopausal Index and the Golombok Rust Inventory of Sexual Satisfaction (GRISS) were used. At the end of the study, each group comprised 50 patients. RESULTS: According to the Kupperman Menopausal Index, there was significant improvement in menopausal symptoms after four months of treatment, especially in relation to hot flashes, when compared to baseline data in both groups. However, no significant differences were observed between groups. There was no improvement in sexual satisfaction after treatment. CONCLUSION: A 12-month treatment with a daily dose of 40 mg Trifolium pratense did not yield a significant improvement in menopausal symptoms and sexual satisfaction.
Subject(s)
Climacteric/drug effects , Isoflavones/adverse effects , Postmenopause/drug effects , Sexual Behavior/drug effects , Trifolium/adverse effects , Aged , Analysis of Variance , Double-Blind Method , Female , Hot Flashes/drug therapy , Humans , Middle Aged , Personal Satisfaction , Prospective Studies , Sexual Behavior/psychology , Time FactorsABSTRACT
OBJECTIVE: To determine if differences exist in hormone-sensitive organ size between infants who were fed soy formula (SF), milk formula (MF), or breast milk (BF). STUDY DESIGN: Breast buds, uterus, ovaries, prostate, and testicular volumes were assessed by ultrasonography in 40 BF, 41 MF, and 39 SF infants at age 4 months. RESULTS: There were no significant feeding group effects in anthropometric or body composition. Among girls, there were no feeding group differences in breast bud or uterine volume. MF infants had greater (P < .05) mean ovarian volume and greater (P < .01) numbers of ovarian cysts per ovary than did BF infants. Among boys, there were no feeding group differences in prostate or breast bud volumes. Mean testicular volume did not differ between SF and MF boys, but both formula-fed groups had lower volumes than BF infants. CONCLUSIONS: Our data do not support major diet-related differences in reproductive organ size as measured by ultrasound in infants at age 4 months, although there is some evidence that ovarian development may be advanced in MF-fed infants and that testicular development may be slower in both MF and SF infants as compared with BF. There was no evidence that feeding SF exerts any estrogenic effects on reproductive organs studied.
Subject(s)
Bottle Feeding , Breast Feeding , Breast/growth & development , Genitalia/growth & development , Infant Formula , Soy Milk , Analysis of Variance , Female , Genitalia/diagnostic imaging , Humans , Infant , Isoflavones/adverse effects , Male , Organ Size , Ovary/diagnostic imaging , Ovary/growth & development , Prospective Studies , Prostate/diagnostic imaging , Prostate/growth & development , Single-Blind Method , Soybean Proteins/adverse effects , Testis/diagnostic imaging , Testis/growth & development , Ultrasonography , Uterus/diagnostic imaging , Uterus/growth & developmentABSTRACT
OBJETIVO: Avaliar os efeitos do tratamento com Trifolium pratense nos sintomas climatéricos e na satisfação sexual de mulheres na pós-menopausa. MÉTODOS: Este estudo foi prospectivo, randomizado, duplo-cego e controlado com placebo. Foram selecionadas 120 mulheres na faixa etária de 45 anos a 65 anos com sintomas climatéricos, amenorreia superior a um ano e sem tratamento nos últimos seis meses. Após a seleção, foram divididas em dois grupos: GT -receberam Trifolium pratense na dose de 40 mg, 1 capsula/dia; GP -receberam placebo (controle), contendo lactose, 1 cápsula/dia. A duração do tratamento foi de 12 meses. As pacientes foram avaliadas clinica e laboratorialmente antes do tratamento e com quatro, oito e 12 meses de tratamento. Foi empregado também o Índice Menopausal de Kupperman (IMK) e o Inventário de Satisfação Sexual Golombok Rust. No final do estudo, cada grupo tinha 50 pacientes. RESULTADOS: Houve melhora significante dos sintomas menopausais após quatro meses de tratamento pelo IMK, principalmente em relação aos fogachos, comparando os dados antes do tratamento nos dois grupos, porém, não houve diferença significante entre os grupos. Não houve melhora na sexualidade antes e após o tratamento. CONCLUSÃO: O tratamento por 12 meses com Trifolium pratense, na dose de 40mg/dia, não promoveu melhora significante dos sintomas menopausais e na satisfação sexual.
OBJECTIVE: To evaluate effects of treatment with Trifolium pratense on climacteric symptoms and sexual satisfaction in postmenopausal women. METHODS: This study was prospective, randomized, double-blind and placebo-controlled. We selected 120 women, aged between 45 and 65 years with climacteric symptoms, with absence of menstruation (amenorrhea) for more then one year and without any treatment in the last six months. After selection, women were divided into two groups: GT received 40 mg of Trifolium pratense (one capsule per day); GP received placebo (control, one capsule of lactose per day). Treatment lasted 12 months and women were evaluated before and after four, eight and twelve months of treatment by clinical (Kupperman Menopausal Index -KMI and the Golombok Rust Inventory of Sexual Satisfaction) and laboratory exams. At study end, each group had 50 patients. RESULTS: There was a significant decrease of symptoms after four months of treatment according to the KMI, mainly of hot flashes in relation to baseline data for both groups, but not between both groups. Evaluation of sexual satisfaction did not disclose any difference in both groups before and after treatment. CONCLUSION: The 40mg/day Trifolium pratense treatment may not ameliorate menopausal symptoms or improve sexual satisfaction.
Subject(s)
Aged , Female , Humans , Middle Aged , Climacteric/drug effects , Isoflavones/adverse effects , Postmenopause/drug effects , Sexual Behavior/drug effects , Trifolium/adverse effects , Analysis of Variance , Double-Blind Method , Hot Flashes/drug therapy , Personal Satisfaction , Prospective Studies , Sexual Behavior/psychology , Time FactorsABSTRACT
OBJECTIVE: To investigate the efficacy of soy isoflavone on climacteric symptoms in postmenopausal women. DESIGN: In this double-blind, randomized, placebo-controlled study, a total of 80 women (mean age = 55.1 years), who reported 5 or more hot flush episodes per day, were randomized to receive either 250 mg of standardized soy extract (Glycine max AT) a total of 100mg/day of isoflavone (n = 40) or placebo (n = 40). Exclusion criteria included: contra-indication for hormone therapy (HT), chronic gastrointestinal diseases, and users of HT within the preceding 6-months. For 10-months, climacteric symptoms were evaluated using a score card and the menopausal Kupperman index. Compliance and safety were also assessed. At baseline and the end of the study, lipid and hormonal profiles, as well as vaginal, mammographic and ultrasonographic parameters were measured. The t-test, Wilcoxon test and ANOVA were used in the statistical analysis. RESULTS: At baseline, the mean number of hot flushes was 9.6 +/- 3.9 per day in the isoflavone group and 10.1+/-4.9 in the placebo group (p>0.05). After 10 months, there was a significant reduction in frequency of hot flushes among isoflavone users when compared to those on placebo (3.1 +/- 2.3 and 5.9 +/- 4.3, respectively) (p<0.001). Kupperman index mean values showed a significant reduction in both groups. However, soy isoflavone was significantly superior to placebo, in reducing hot flush severity (69.9% and 33.7%, respectively) (p<0.001). Endometrial thickness, mammography, vaginal cytology, lipids and hormonal profile did not change in both groups. No serious adverse event related to isoflavone treatment was reported. CONCLUSIONS: The soy isoflavone extract exerted favorable effects on vasomotor symptoms and good compliance, providing a safe and effective alternative therapeutic for postmenopausal women.
Subject(s)
Glycine max , Hot Flashes/drug therapy , Isoflavones/therapeutic use , Phytotherapy , Plant Extracts/therapeutic use , Double-Blind Method , Female , Hot Flashes/pathology , Humans , Isoflavones/administration & dosage , Isoflavones/adverse effects , Middle Aged , Plant Extracts/administration & dosage , Plant Extracts/adverse effects , Postmenopause , Severity of Illness Index , Treatment OutcomeABSTRACT
Soy and derivative diets deliver large doses of isoflavones to human and animals throughout their lifespan, including gestation. Epidemiologic and experimental data suggest that the consumption of soybean containing foods may protect against cardiovascular disease and decrease breast, prostate and endometrial cancer risk. Based on animal and in vitro studies, however, concerns have been raised that consumption of isoflavones may cause potential adverse effects on the reproductive tract and behavior. The aim of this study was to investigate the effects of chronic consumption of a soy meal containing diet or soy isoflavones supplement on the morphology of reproductive organs, semen quality, age that males reached puberty, and sexual behavior of male rabbits. With this purpose, 16 female rabbits were randomly assigned to receive: (1) a soy- and alfalfa-free diet; (2) a soy- and alfalfa-free diet supplemented with 5mg/kg body wt./day of soy isoflavones; (3) a soy- and alfalfa-free diet supplemented with 20mg/kg body wt./day of soy isoflavones; (4) a diet containing 18% of soy meal, throughout the gestation and lactation. After weaning, male offspring received the same diet, which was given to the respective mother. The age that males reached puberty, semen characteristics and sexual behavior were evaluated in these animals. At 33 weeks of age, the reproductive organs were submitted to histological evaluation. Rabbits, which received large amounts of isoflavones (20mg/kg body wt./day) had a lesser food intake, body weight and semen volume. Spermatogenesis, morphology of male genital organs and sexual behavior did not differ significantly from the control group. We conclude that chronic dietary treatment with soy based diet or soy isoflavones have no adverse effects on the observed reproductive patterns of male rabbits.
Subject(s)
Animal Nutritional Physiological Phenomena , Glycine max , Isoflavones/administration & dosage , Rabbits/physiology , Reproduction/physiology , Semen/physiology , Animals , Dietary Supplements , Dose-Response Relationship, Drug , Isoflavones/adverse effects , Male , Random Allocation , Reproduction/drug effects , Semen/drug effects , Sexual Behavior, Animal/drug effects , Sexual Behavior, Animal/physiology , Sexual Maturation/drug effects , Sexual Maturation/physiologyABSTRACT
OBJETIVO: Este estudo descritivo e prospectivo teve como objetivo avaliar o endométrio de mulheres menopausadas antes e após seis meses de uso de isoflavonas totais. MÉTODOS: Foi realizado um ensaio clínico não controlado, do tipo antes e depois, em 32 mulheres na pós-menopausa, com idade entre 40 e 60 anos, que receberam 80 mg por dia de isoflavonas totais (Trifolium pratense-Climadil®) durante seis meses. Foram avaliadas no início e no final do tratamento por meio de ultra-sonografia pélvica transvaginal, histeroscopia e biópsia endometrial. Os dados coletados foram registrados no programa Epi Info, versão 6,04b e a análise dos dados foi realizada pelo programa estatístico SAS versão 8,2, considerando um nível de significância (alfa) de 0,05 e um poder (1-beta) de 0,80. As variações médias da espessura endometrial, dos achados histeroscópicos e histológicos, entre os instantes iniciais e após seis meses, foram avaliadas pelo teste t de Student para dados pareados. RESULTADOS: Dentre as 32 mulheres que participaram do estudo, seis apresentaram sangramento vaginal e três, alterações endometriais. Duas mulheres desenvolveram proliferação endometrial e uma, hiperplasia endometrial. Não houve alterações significativas em relação ao espessamento endometrial ao ultra-som. CONCLUSÃO: Neste estudo, três mulheres que utilizaram isoflavonas durante seis meses apresentaram modificações endometriais que sugeriram estímulo endometrial.
OBJETIVE: To evaluate the endometrium of menopausal women before and after six months use of total isoflavone. METHODS: A non-controlled clinical, type "before and after" trial was carried out with 32 post-menopause women, between 40 and 60 years of age. They received 80mg/day of total isoflavones obtained from Trifolium pratense (Climadilâ) during six months. They were evaluated at the beginning and end of treatment by transvaginal pelvic ecography, hysteroscopy and endometrial biopsy. DATA ANALYSIS: Data collected were registered by means of the Epi info, version 6.04b software, data analysis was made using the SAS version 8.2 statistics program, considering a significance level (alpha) of 0.05 and a 0.80 power (1-beta). In order to study the average variation of endometrial thickness and variation of the hysteroscopic and hystologic findings the t Student test for paired data was used. RESULTS: Among the 32 participant women, six presented vaginal bleeding and three presented endometrial alteration when compared to the initial exams. Two of the women developed endometrial cell proliferation and one of them endometrial hiperplasia. There were no significant alterations in relation to endometrial thickness. CONCLUSION: In this study, three women who used isoflavones during the six month period presented endometrial activity.
Subject(s)
Humans , Female , Adult , Middle Aged , Endometrium/drug effects , Endometrium/pathology , Isoflavones/adverse effects , Menopause , Uterine Diseases/etiology , Biopsy , Endometrial Hyperplasia/etiology , Hot Flashes , Hyperplasia , Hysteroscopy , Prospective Studies , Time Factors , Uterine Diseases/diagnosis , Uterine Hemorrhage/etiologyABSTRACT
OBJECTIVE: To evaluate the endometrium of menopausal women before and after six months use of total isoflavone. METHODS: A non-controlled clinical, type "before and after" trial was carried out with 32 post-menopause women, between 40 and 60 years of age. They received 80 mg/day of total isoflavones obtained from Trifolium pratense (Climadilâ) during six months. They were evaluated at the beginning and end of treatment by transvaginal pelvic ecography, hysteroscopy and endometrial biopsy. DATA ANALYSIS: Data collected were registered by means of the Epi info, version 6.04 b software, data analysis was made using the SAS version 8.2 statistics program, considering a significance level (alpha) of 0.05 and a 0.80 power (1-beta). In order to study the average variation of endometrial thickness and variation of the hysteroscopic and hystologic findings the t Student test for paired data was used. RESULTS: Among the 32 participant women, six presented vaginal bleeding and three presented endometrial alteration when compared to the initial exams. Two of the women developed endometrial cell proliferation and one of them endometrial hyperplasia. There were no significant alterations in relation to endometrial thickness. CONCLUSION: In this study, three women who used isoflavones during the six month period presented endometrial activity.
Subject(s)
Endometrium/drug effects , Endometrium/pathology , Isoflavones/adverse effects , Menopause , Uterine Diseases/etiology , Adult , Biopsy , Endometrial Hyperplasia/etiology , Female , Hot Flashes , Humans , Hyperplasia , Hysteroscopy , Middle Aged , Prospective Studies , Time Factors , Uterine Diseases/diagnosis , Uterine Hemorrhage/etiologyABSTRACT
Los fitoestrógenos son sustancias ambientales naturales, producidas por plantas, que a pesar de su estructura química distinta de los estrógenos, actúan como tales. Estudios en adultos sugieren que tendrían efectos protectores para cánceres hormonodependientes (de próstata y mama), dislipidemias y de la mineralización ósea. Se clasifican en isoflavonas, cumestanos y lignanos, y se encuentran principalmente en legumbres y poroto de soya, brotes de poroto, forraje y granos, y en cereales de grano entero y semillas, respectivamente. Estudios recientes han demostrado que los alimentos infantiles, incluyendo algunas fórmulas lácteas, yogur y alimentos de soya, contienen cantidades considerables de fitoestrógenos. Los efectos de estos sobre la salud infantil no han sido del todo aclarados. Existen evidencias epidemiológicas y clínicas de que al actuar como estrógenos débiles prodrían determinar adelanto de los eventos puberales y telarquia en la niña y ginecomastia en el varón. Se hace una revisión del tema y se plantea la necesidad de realizar estudios destinados a aclarar los efectos de los estrógenos ambientales sobre la salud infantil